Amneal unveils FDA approved generic fluphenazine for treating schizophrenia
13 July 2020 -

Pharmaceutical company Amneal Pharmaceuticals Inc (NYSE:AMRX) reported on Friday the receipt of the Abbreviated New Drug Application (ANDA) approval from the US Food and Drug Administration (FDA) for the generic Fluphenazine Hydrochloride Tablets USP in 1mg, 2.5mg, 5mg and 10mg for treatment of schizophrenia.

The company added that the Fluphenazine Hydrochloride is the generic version of Prolixin for treatment of schizophrenia.

Effective immediately, the company has initiated commercialization activities of generic Fluphenazine Hydrochloride across all dosages.

In conjunction, the US annual sales for Fluphenazine Hydrochloride Tablets for the 12 months ended May 2020 were approximately USD143m, according to IQVIA, a leading healthcare data and analytics provider.